Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2018-03-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-17-1108PMID 29559545PMCID PMC6053917
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Centrosome Amplification and Cancer: A Question of Sufficiency.

  2017cited by this paper
• Aneuploidy Causes Non-genetic Individuality.

  2017cited by this paper
• Cep78 controls centrosome homeostasis by inhibiting EDD‐DYRK2‐DDB1VprBP

  2017cited by this paper
• Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer

  2017influential reference
• The daughter centriole controls ciliogenesis by regulating Neurl-4 localization at the centrosome

  2017cited by this paper
• Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2

  2016influential reference
• Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.

  2016cited by this paper
• A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.

  2015cited by this paper
• Liver polyploidy: Dr Jekyll or Mr Hide?

  2015cited by this paper
• Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown

  2015influential reference
• CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110.

  2015influential reference
• The centrosome duplication cycle in health and disease

  2014cited by this paper
• Causes and consequences of centrosome abnormalities in cancer

  2014cited by this paper
• Oncogene-like induction of cellular invasion from centrosome amplification

  2014cited by this paper
• Dragging ras back in the ring.

  2014cited by this paper
• CP110 and its network of partners coordinately regulate cilia assembly

  2013cited by this paper
• USP33 regulates centrosome biogenesis via deubiquitination of the centriolar protein CP110

  2013influential reference
• KRAS mutation: should we test for it, and does it matter?

  2013cited by this paper
• Cell Biology: DUBing CP110 Controls Centrosome Numbers

  2013cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• Let's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy

  2012cited by this paper
• Abstract 5374: Significance of ADCC for the action of trastuzumab quantified by novel procedures

  2012cited by this paper
• Polyploidy and liver proliferation.

  2012cited by this paper
• GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo.

  2012cited by this paper
• Neurl4, a novel daughter centriole protein, prevents formation of ectopic microtubule organizing centres

  2012cited by this paper
• Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair.

  2012cited by this paper
• A critical role of integrin-linked kinase, ch-TOG and TACC3 in centrosome clustering in cancer cells

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Centriolar kinesin Kif24 interacts with CP110 to remodel microtubules and regulate ciliogenesis.

  2011cited by this paper
• Anaphase Catastrophe Is a Target for Cancer Therapy

  2011influential reference
• The G1 phase Cdks regulate the centrosome cycle and mediate oncogene-dependent centrosome amplification

  2011cited by this paper
• Regulating the transition from centriole to basal body

  2011cited by this paper
• A Clinical Overview of Centrosome Amplification in Human Cancers

  2011cited by this paper
• SCFCyclin F controls centrosome homeostasis and mitotic fidelity via CP110 degradation

  2010cited by this paper
• Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.

  2010cited by this paper
• Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

  2010cited by this paper
• Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe

  2010influential reference
• Proteins Required for Centrosome Clustering in Cancer Cells

  2010cited by this paper
• The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2

  2010cited by this paper
• Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

  2009cited by this paper
• CPAP is a cell-cycle regulated protein that controls centriole length

  2009cited by this paper
• A Mechanism Linking Extra Centrosomes to Chromosomal Instability

  2009cited by this paper
• Multipolar Spindle Pole Coalescence Is a Major Source of Kinetochore Mis-Attachment and Chromosome Mis-Segregation in Cancer Cells

  2009cited by this paper
• Centrosome function in cancer: guilty or innocent?

  2009cited by this paper
• Overly long centrioles and defective cell division upon excess of the SAS-4-related protein CPAP.

  2009cited by this paper
• Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells

  2009cited by this paper
• Centrosomes and cancer: how cancer cells divide with too many centrosomes

  2009cited by this paper
• How do anti-mitotic drugs kill cancer cells?

  2009cited by this paper
• Control of centriole length by CPAP and CP110.

  2009cited by this paper
• Explaining the preponderance of Kras mutations in human cancer: An isoform-specific function in stem cell expansion

  2008cited by this paper
• Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes.

  2008cited by this paper
• Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents

  2008cited by this paper
• Multiple centrosomes: together they stand, divided they fall.

  2008cited by this paper
• CP110 suppresses primary cilia formation through its interaction with CEP290, a protein deficient in human ciliary disease.

  2008cited by this paper
• Centrosome amplification can initiate tumorigenesis in flies.

  2008cited by this paper
• Plk4-induced centriole biogenesis in human cells.

  2007cited by this paper
• Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen.

  2007cited by this paper
• KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

  2007cited by this paper
• Cep97 and CP110 suppress a cilia assembly program.

  2007cited by this paper
• Centrosome biogenesis and function: centrosomics brings new understanding

  2007cited by this paper
• Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations

  2007cited by this paper
• K-ras mutations in non-small-cell lung carcinoma: a review.

  2006cited by this paper
• CP110 cooperates with two calcium-binding proteins to regulate cytokinesis and genome stability.

  2006cited by this paper
• Origins and consequences of centrosome aberrations in human cancers

  2006cited by this paper
• Clinical implication of centrosome amplification in plasma cell neoplasm.

  2006cited by this paper
• Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability

  2005cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• Spindle Multipolarity Is Prevented by Centrosomal Clustering

  2005cited by this paper
• Mutant KRAS, chromosomal instability and prognosis in colorectal cancer.

  2005cited by this paper
• The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway

  2004cited by this paper
• Aneuploidy and cancer

  2004cited by this paper
• Centrosome aberrations: cause or consequence of cancer progression?

  2002influential reference
• Centrosome composition and microtubule anchoring mechanisms.

  2002cited by this paper
• In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)

  2002cited by this paper
• Centrosome replication, genomic instability and cancer

  2002cited by this paper
• CP110, a cell cycle-dependent CDK substrate, regulates centrosome duplication in human cells.

  2002influential reference
• Centrosome amplification drives chromosomal instability in breast tumor development

  2002cited by this paper
• Cyclin F Is Degraded during G2-M by Mechanisms Fundamentally Different from Other Cyclins*

  2002cited by this paper
• Managing the centrosome numbers game: from chaos to stability in cancer cell division.

  2001cited by this paper
• Aneuploidy and cancer

  2000cited by this paper
• K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.

  1999cited by this paper
• Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity.

  1998cited by this paper
• Centrosome defects and genetic instability in malignant tumors.

  1998cited by this paper
• Mitosis in a cell with multiple centrioles

  1982cited by this paper

• CDK2 inhibition produces a persistent population of polyploid cancer cells

  2025cites this paper
• P129, a pyrazole ring-containing isolongifolanone-derivate: synthesis and investigation of anti-glioma action mechanism

  2024cites this paper
• Whole-Genome Duplication and Genome Instability in Cancer Cells: Double the Trouble

  2023cites this paper
• Isogenic Cell Lines Derived from Specific Organ Metastases Exhibit Divergent Cytogenomic Aberrations

  2023cites this paper
• Midkine inhibitor (iMDK) induces apoptosis of primary effusion lymphoma via G2/M cell cycle arrest.

  2022cites this paper
• Cyclin B/CDK1 and Cyclin A/CDK2 phosphorylate DENR to promote mitotic protein translation and faithful cell division

  2022cites this paper
• Role of Senescence in Tumorigenesis and Anticancer Therapy

  2022cites this paper
• Icaritin inhibits CDK2 expression and activity to interfere with tumor progression

  2022cites this paper
• Nondiploid cancer cells: Stress, tolerance and therapeutic inspirations.

  2022cites this paper
• Clinical Applications of Aneuploidies in Evolution of NSCLC Patients: Current Status and Application Prospect

  2022cites this paper
• NEDD8-activating enzyme inhibition induces cell cycle arrest and anaphase catastrophe in malignant T-cells

  2021cites this paper
• TRIGGERING ANAPHASE CATASTROPHE TO COMBAT ANEUPLOID CANCERS.

  2020cites this paper
• A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers

  2020cites this paper
• A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer

  2020cites this paper
• Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy

  2019cites this paper
• Targeting CDK2 in cancer: challenges and opportunities for therapy.

  2019cites this paper
• Threonine Tyrosine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy

  2019cites this paper
• Targeting centrosome amplification, an Achilles' heel of cancer

  2019cites this paper